

# ELC Cooperative Agreement

As of July 2021

CDC's Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement (ELC) provides financial support and technical assistance to the nation's health departments to support their efforts to **detect, prevent, and respond to emerging infectious diseases**. The ELC also distributes supplemental funding on behalf of CDC for emergency response efforts, such as those for the influenza H1N1, Zika, and Ebola epidemics, and most recently, the COVID-19 pandemic.

ELC's 64 recipients, which consist of state, large local, and U.S. territory and affiliate health departments, serve as the foundation for our national public health infrastructure and are **integral to the nation's ability to tackle infectious disease threats**.

In addition to a commitment to providing high-quality technical assistance, subject matter expert support, and financial assistance, the ELC accomplishes its mission through a unique structure of **four robust public health programs; five cross-cutting projects** focusing on leadership, integration, flexibility, and sustainability; and a **range of disease-specific projects**.

## Our Structure: What Sets ELC Apart



Flexible funding provides recipients the ability to meet their own changing needs, instead of a one-size-fits-all strategy



Disease-specific projects allow for prioritization of health topics specific to certain areas or populations, such as Legionnaire's disease or vaccine-preventable diseases



Funding for leadership and management supports strategic planning and management of ELC resources



Cross-cutting projects and programs enhance collaboration between state epidemiology and laboratory, as well as local public health departments

**In July 2021, ELC awarded approximately \$238M to its 64 recipients** to continue the crucial work of health departments around the United States

Learn more about ELC at [www.cdc.gov/elc](http://www.cdc.gov/elc)

## 2021–2022 ELC FUNDING

Programs	Recipients	Funding
Cross-cutting Epidemiology & Laboratory Capacity Program	63	\$23,120,106
Foodborne, Waterborne, Enteric, & Environmentally Transmitted Diseases Program	58	\$64,579,707
Healthcare-associated Infections & Antibiotic Resistance Program	59	\$56,506,707
Vector-borne Diseases Program	63	\$14,199,262

### Cross-Cutting Projects

ELC Leadership, Management, & Administration	64	\$5,386,461
Health Information Systems Capacity	64	\$23,999,999
Data Modernization	64	\$200,000,000*
Impact and Evaluation	4	\$395,831
Cross-Cutting Emerging Issues Project: Enhanced Surveillance, Outbreak Investigation Response & Reporting, Surge Efforts & Interventions	TBD	Available for emerging issues

### Disease-Specific Projects

Mycotics: Detecting & Preventing Fungal Infections	32	\$700,000
Binational Border Infectious Disease Surveillance (BIDS) Program	4	\$1,490,891
Global Migration, Border Interventions, and Migrant Health	1	\$66,109
Prion Surveillance	6	\$391,025
Rabies Surveillance	25	\$120,000
Parasitic Diseases Surveillance	TBD	TBD
Enhanced Vaccine-Preventable Disease (VPD)	60	\$17,106,476
Legionnaires' Disease Prevention	36	\$3,197,327
Influenza Surveillance and Diagnostic Testing	57	\$9,358,568
Non-Influenza Respiratory Diseases: Diagnostics, Reporting, and Surveillance	38	\$1,000,000
Strengthening United States Response to Resistant Gonorrhea (SURRG)	8	\$5,096,918
Gonococcal Isolate Surveillance Project (GISP)	20	\$500,000
Catalyzing Congenital Syphilis Prevention (CCSP)	4	\$1,589,624
Human Papillomavirus Surveillance Among Men	3	\$235,844
Infants with Congenital Exposures: Surveillance and Monitoring to Emerging Infectious Diseases and Other Health Threats	27	\$9,136,913

\*DMI award made through COVID funding, not as part of the \$238M in Core ELC funding

